Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AVANDARYL | SB Pharmco | N-021700 DISCN | 2005-11-23 | 5 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
duetact | New Drug Application | 2022-10-24 |
glimepiride | ANDA | 2024-01-16 |
pioglitazone and glimepiride | NDA authorized generic | 2021-12-16 |
pioglitazone hydrochloride and glimepiride | ANDA | 2018-06-18 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 8 | 13 | 92 | 71 | 32 | 213 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | 6 | 4 | — | 11 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | 2 | 3 | 6 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 1 | — | 2 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | 2 | — | 2 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | 1 | — | 1 |
Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | 1 | — | 1 |
Heart disease risk factors | D000082742 | — | — | — | — | — | 1 | — | 1 |
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Coronary disease | D003327 | — | — | — | — | 1 | — | 1 | 2 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | 1 | 2 |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
Dyslipidemias | D050171 | HP_0003119 | — | — | — | 1 | — | — | 1 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | 1 | 2 |
Heart failure | D006333 | HP_0001635 | I50 | — | 1 | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 15 | — | — | — | 3 | 18 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
Cohort studies | D015331 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Glimepiride |
INN | glimepiride |
Description | Glimepiride is a sulfonamide, a N-acylurea and a N-sulfonylurea. It has a role as a hypoglycemic agent and an insulin secretagogue. |
Classification | Small molecule |
Drug class | antidiabetics |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O |
PDB | — |
CAS-ID | 93479-97-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1481 |
ChEBI ID | 5383 |
PubChem CID | 3476 |
DrugBank | DB00222 |
UNII ID | 6KY687524K (ChemIDplus, GSRS) |